{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-24-000057","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.768703+00:00","generated_at":"2026-06-02T19:16:51.676372+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib","bullets":["Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.","Pro forma cash, cash equivalents and marketable securities $396M as of March 31, 2024.","PROSERA Phase 3 PAH study topline results expected Q4 2025; registrational Phase 3 PH-ILD to start mid-2025.","Net loss $41.9M ($0.19 per share) for Q1 2024 vs $49.2M ($0.52 per share) in Q1 2023.","R&D expenses $32.4M in Q1 2024 down from $37.8M YoY, primarily due to terminated programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-24-000057","json":"https://secwatch.observer/filing/0001728117-24-000057.json","markdown":"https://secwatch.observer/filing/0001728117-24-000057.md","text":"https://secwatch.observer/filing/0001728117-24-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000057/0001728117-24-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000057/goss-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:16:51.676372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"162f49b0fd35f013cde75935cc700fb97532519a","claim":"Gossamer Bio, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $41.9 million, or $0.19 per share, EPS $0.19 per share.","evidence_excerpt":"On May 7, 2024, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811724000057/0001728117-24-000057-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2024, was $41.9 million, or $0.19 per share"},{"label":"EPS","value":"$0.19 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}